DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
41	巨細胞性動脈炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03827018 (ClinicalTrials.gov)	December 21, 2018	25/1/2019	KPL-301 for Subjects With Giant Cell Arteritis	A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis	Giant Cell Arteritis	Combination Product: mavrilimumab;Combination Product: placebo	Kiniksa Pharmaceuticals, Ltd.	NULL	Active, not recruiting	50 Years	85 Years	All	70	Phase 2	United States;Australia;Belgium;Croatia;Estonia;Germany;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovenia;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

December 21, 2018

25/1/2019

KPL-301 for Subjects With Giant Cell Arteritis

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis

Giant Cell Arteritis

Combination Product: mavrilimumab;Combination Product: placebo

Kiniksa Pharmaceuticals, Ltd.

NULL

Active, not recruiting

50 Years

85 Years

All

Phase 2

United States;Australia;Belgium;Croatia;Estonia;Germany;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovenia;Spain;United Kingdom